A diabetes drug distributed underneath the model title Wegovy may provide an acceptable and useful weight reduction therapy for some 93 million adults within the US, in response to a brand new research.


That is lots of people by any measure. Projections counsel it might imply some 43 million fewer folks with weight problems, and the prevention of round 1.5 million coronary heart assaults, strokes, and different cardiovascular issues over the course of 10 years.

The estimates, from a crew on the College of California, Irvine (UCI) within the US, are based mostly on a latest trial involving 1,961 adults, focused at folks with weight problems and who got a weekly 2.4 milligram dose of semaglutide, the pharmaceutical on which Wegovy relies.

Weight loss chart
Estimated physique weight reductions on a course of semaglutide. (Wong et al., Cardiovascular Medicine and Remedy, 2023)

Trialing a dosage already accepted by the US Meals and Drug Administration (FDA), the consequences had been dramatic: a median physique weight discount of 14.9 %, and a discount in danger components related to cardiovascular issues, together with blood stress and fatty compounds known as lipids.


“It is without doubt one of the greatest advances within the weight problems and cardiovascular drugs world,” says Nathan Wong, a professor of medication at UCI.

“We now have a weight management remedy that additionally considerably reduces cardiovascular occasions past the diabetes inhabitants the place it was initially studied.”

Semaglutide works by mimicking the GLP-1 hormone launched naturally by our intestine as we eat. One of many hormone’s jobs is to extend manufacturing of insulin and thus cut back blood sugar (glucose) ranges, which is why it is beforehand been used to deal with diabetes.

Nonetheless, scientists have additionally found that it targets the components of our brains that inform us we’re full, suppressing urge for food. This could result in vital weight reduction – so long as it is mixed with a managed food plan and train.

The researchers got here up with their 93 million determine by extrapolating the standards for the earlier trial to the broader inhabitants, however they emphasize that no drug ought to be taken with out a session with a physician.

Proper now semaglutide is accepted to be used for persistent weight administration in adults who’re overweight or obese, and who even have not less than one weight-related situation – comparable to hypertension, kind 2 diabetes, or excessive ldl cholesterol.

A broader roll-out of the drug and others prefer it may meet a rising want: by 2030, half of US adults are anticipated to be thought-about overweight with almost 1 in 4 falling right into a severely overweight class. This places many at better danger of a wealth of well being issues, together with coronary heart illness and coronary heart failure.

“It ought to be thought-about for sufferers who’re overweight or obese with different danger components the place heart problems is their main reason for incapacity and demise,” says Wong.

The analysis has been revealed in Cardiovascular Medicine and Remedy.

Deixe um comentário

O seu endereço de e-mail não será publicado. Campos obrigatórios são marcados com *